SMC Follows NICE And Backs Lilly’s Verzenios In Advanced Breast Cancer
Executive Summary
The SMC has given the all clear to funding for Lilly’s Verzenios for breast cancer, Richter’s Reagila for schizophrenia, and MSD’s Keytruda for melanoma. However, it rejected Alliance’s Xonvea for sickness in pregnancy because the evidence on benefits and cost effectiveness did not stack up.
You may also be interested in...
New Kisqali Combination Joins Verzenios In England’s Cancer Drugs Fund
Two of the three companies vying for an additional share of England’s CDK4/6 inhibitor market have now secured reimbursement for the use of their products in combination with fulvestrant for advanced breast cancer.
Lilly Scores New Treatment Option For Verzenios In England
Health technology assessment body NICE says that Verzenios when used with fulvestrant can be used to treat advanced breast cancer via the Cancer Drugs Fund, giving Eli Lilly the edge in this space for now over rival CDK4/6 manufacturers, Pfizer and Novartis.
UK Explains New Rules On Parallel Imports From EU
Guidance from the Medicines and Healthcare products Regulatory Agency says that the packaging of parallel imported medicines must make clear that they are for the UK market only.